source
- Regeneron defends M&A stance as cash hoard reaches $18 billion amid trial setbacksAnalysts on Regeneron's second‑quarter earnings call questioned the company's lack of merger and acquisition activity, pointing to an $18 billion cash reserve and recent clinical trial setbacks. C…
- UCB shares dip as investors worry forecast may be too optimistic despite Bimzelx sales beatUCB reported that sales of its lead drug Bimzelx exceeded analysts' expectations for the quarter. However, the company also gave a full-year revenue outlook that some investors view as overly opti…